Evidence map›Paper›PMID 40478247›Full record

ArticleClinical and translational gastroenterology2025

Association of Primary Language With Treatment and Outcomes in Inflammatory Bowel Disease.

Laura C Sahyoun, Veronica Chavez, Jaya Vasudevan, Lawrence Kogan, Bhuvana Mukkamala, Maria Goretti Ochi, Thritha Anand, Zehra Ahmed, Zhouwen Tang, Linda A Feagins and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura C SahyounDivision of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-4094-3682
Veronica ChavezDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Jaya VasudevanDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Lawrence KoganDepartment of Digestive Diseases, Yale New Haven Hospital, New Haven, Connecticut, USA.
Bhuvana MukkamalaDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Maria Goretti OchiDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Thritha AnandDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Zehra AhmedDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Zhouwen TangDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Linda A FeaginsDivision of Gastroenterology and Hepatology, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA.
Jill K J GaidosDepartment of Digestive Diseases, Yale New Haven Hospital, New Haven, Connecticut, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAs rates of inflammatory bowel disease (IBD) rise among non-English-speaking populations, it is imperative to better understand the impact of language barriers and cultural differences on disease management.

methodsThe multicenter, retrospective, cohort study of adult patients with IBD who spoke a language other than English, matched 1:2 to English-speaking controls. Patients were enrolled at their first clinic visit and then followed up to 12 months. Advanced therapy (AT) was defined as a biologic or small molecule. Primary outcome was the rate of AT use between cohorts. Secondary outcomes included rates of AT initiation and corticosteroid-free clinical remission at 6 and 12 months.

resultsOne hundred forty-four patients with IBD (48 non-English speakers, 96 English speakers) were included in this study. Both cohorts had similar baseline disease activity based on physician global assessment; however, non-English-speaking patients had significantly higher rates of baseline elevated fecal calprotectin (91.7% vs 50%, P = 0.014). After multivariate analysis to adjust for baseline differences, we found no difference in prior or current AT use. Rates of initiation of AT were similar between the 2 groups at 6- and 12-month follow-up. Adjusted rates of corticosteroid-free clinical remission were not different at 6 and 12 months. DISCUSSION: Primary language spoken did not significantly affect the rates of AT use or overall IBD disease activity in 2 academic practices. Future studies are warranted to understand the effect of language on medication adherence, patient satisfaction and understanding, and disease outcomes.

Indexed as

Biological ProductsCommunication BarriersInflammatory Bowel DiseasesLanguageAdrenal Cortex HormonesAdultFemaleFollow-Up StudiesHumansLeukocyte L1 Antigen ComplexMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeAdrenal Cortex HormonesBiological ProductsLeukocyte L1 Antigen Complexdisease outcomeshealthcare disparitiesinflammatory bowel disease

Identifiers

PMID40478247
PMCPMC12377305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.